Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care.Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and less cardiotoxicity than other comparable agents. Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML) exploring anti-cancer plus cardio-protection in synergy with known standards of care.

MycRx has had an active Myc drug discovery program for >4 years. It has built a solid body of holistic data demonstrating that its small molecules directly engage Myc, leading to on-target downstream anti-cancer effects and resulting in the degradation of Myc protein. The Company is now focused on the transition of its promising exemplar chemistry into optimized lead candidates capable of entering IND-enabling studies. The firm’s aspiration is to become ‘the Myc company’, developing a stable of Myc-targeting compounds, tuned to the specific biological roles of Myc and subsequent clinical translation. Originally based in Melbourne, Australia, MycRx recently closed a Series A US-led venture capital round and has restructured as a Delaware corporation, with a growing North American Management team.

Amala Therapeutics is a biotech start-up focused on preserving muscle in diseased states.

Hula Therapeutics Inc. is focused on delivering better therapies for children and young adults with cancer. It is a collaboration between Children's Hospital of Philadelphia (CHOP) and Myrio Therapeutics, using CHOP's disease expertise and target identification with Myrio's novel antibody platform. Two programs should enter the clinic in 2024, the first for neuroblastoma and the second for medulloblastoma and gliomas. Some of the breakthrough work from this collaboration was published in Nature in 2021 https://www.nature.com/articles/s41586-021-04061-6 .We are on a mission to have a significant positive impact on the lives of kids with cancer and their families.

Cancer will have no place to hide...Myrio Therapeutics ("Myrio", formerly Affinity Bioscience) is revolutionizing the field of immuno-oncology by enabling antibody-based therapies to attack targets that are inside cells. Proteins inside cells are routinely broken down into peptides which are displayed on the cell surface by Major Histocompatibility Complex (MHC), the targets of T-Cells. Myrio’s protein-display system can discover antibodies against difficult to hit targets such as peptide-MHC complexes. This ability significantly increases the number of addressable cancer or viral targets. Based on fully-human sequences, discovered antibodies can be formatted for a specific purpose, from targeting CAR-T cells, antibody-drug conjugates, bispecifics or traditional antibodies.Myrio’s discovery platform can generate high affinity (low nM/pM) and highly selective scFv (antibody fragments) in a matter of days, allowing for rapid evaluation and optimization of product candidates. Affinity is seeking partnerships to fully exploit the potential of its technology whilst also building an in-house portfolio of products.

Big Cap European pharma analyst. Also involved in brokerships/IPOs of several biotechnology companies.